ESTRO 2025 - Abstract Book

S1323

Clinical - Lung

ESTRO 2025

The median follow-up was 29.1 months (range: 2.2–120.4 months), during which we observed 6 local recurrences, 9 ipsilateral pulmonary metastases, 5 contralateral pulmonary metastases, 6 lymph node metastases, 6 distant metastases, and 20 deaths. Among all eligible patients, the 3 and 5-year LC, PFS, DSS, and OS rates were 89.4%, 51.9%, 92.0%, and 70.6%, and 89.4%, 39.1%, 83.3%, and 59.7%, respectively. No significant differences in LC were observed between two groups with T stage and CTR (Figures 1A and 2A). In univariate analyses, pathologically confirmed Sq was associated with a worse LC rate (p = 0.022). Patients with T1a or less (≤ T1a), and with CTR ≤ 0.25 had significantly better PFS than those with T1b–c or with CTR > 0.25 (Figures 1B and 2B). In addition, there were no recurrences, metastases, or deaths in patients with tumours of CTR ≤ 0.25. Among patients with non-Sq tumours, significant differences were observed in PFS between the ≤ T1a and T1b–c group and also the CTR ≤ 0.25 and > 0.25 groups (p = 0.013 and 0.047, respectively). Conclusion: In stage 0–IA lung cancer treated with SBRT, tumours classified as ≤ T1a showed a better PFS than T2b–c. SBRT for early-stage lung cancer with a low CTR of ≤ 0.25 achieved excellent outcomes that were comparable with surgery.

Keywords: SBRT, CTR, Lung cancer